You B, Purdy C, Copeland LJ, Swisher EM, et al. Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study. J Clin Oncol 2022 Oct 17:JCO2201207. doi: 10.1200/JCO.22.01207.
PMID: 36252167